nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—coronary artery disease	0.0977	1	CbGaD
Canagliflozin—ORM1—Penbutolol—coronary artery disease	0.0481	0.0816	CbGbCtD
Canagliflozin—ORM1—Pitavastatin—coronary artery disease	0.042	0.0714	CbGbCtD
Canagliflozin—ABCC2—Olmesartan—coronary artery disease	0.0355	0.0603	CbGbCtD
Canagliflozin—ABCC2—Telmisartan—coronary artery disease	0.0284	0.0482	CbGbCtD
Canagliflozin—ABCC2—Pitavastatin—coronary artery disease	0.0284	0.0482	CbGbCtD
Canagliflozin—ABCC2—Ezetimibe—coronary artery disease	0.0209	0.0355	CbGbCtD
Canagliflozin—ABCC2—Simvastatin—coronary artery disease	0.0194	0.033	CbGbCtD
Canagliflozin—ABCC2—Lovastatin—coronary artery disease	0.019	0.0323	CbGbCtD
Canagliflozin—ABCC2—Pravastatin—coronary artery disease	0.019	0.0323	CbGbCtD
Canagliflozin—ALB—Pitavastatin—coronary artery disease	0.0177	0.03	CbGbCtD
Canagliflozin—ABCC2—Atorvastatin—coronary artery disease	0.0173	0.0294	CbGbCtD
Canagliflozin—ALB—Valsartan—coronary artery disease	0.0172	0.0292	CbGbCtD
Canagliflozin—ABCB1—Ticagrelor—coronary artery disease	0.0171	0.0291	CbGbCtD
Canagliflozin—ABCC2—Furosemide—coronary artery disease	0.0162	0.0275	CbGbCtD
Canagliflozin—ALB—Rosuvastatin—coronary artery disease	0.013	0.0221	CbGbCtD
Canagliflozin—UGT2B4—pericardium—coronary artery disease	0.0128	0.312	CbGeAlD
Canagliflozin—ALB—Acetylsalicylic acid—coronary artery disease	0.0127	0.0216	CbGbCtD
Canagliflozin—ALB—Captopril—coronary artery disease	0.0125	0.0213	CbGbCtD
Canagliflozin—ABCB1—Clopidogrel—coronary artery disease	0.0106	0.018	CbGbCtD
Canagliflozin—ABCB1—Perindopril—coronary artery disease	0.0106	0.018	CbGbCtD
Canagliflozin—CYP3A4—Ticagrelor—coronary artery disease	0.0103	0.0174	CbGbCtD
Canagliflozin—ALB—Furosemide—coronary artery disease	0.0101	0.0171	CbGbCtD
Canagliflozin—ALB—Losartan—coronary artery disease	0.00988	0.0168	CbGbCtD
Canagliflozin—ABCB1—Pitavastatin—coronary artery disease	0.00925	0.0157	CbGbCtD
Canagliflozin—ABCB1—Telmisartan—coronary artery disease	0.00925	0.0157	CbGbCtD
Canagliflozin—CYP3A4—Fenofibrate—coronary artery disease	0.00914	0.0155	CbGbCtD
Canagliflozin—ABCB1—Enalapril—coronary artery disease	0.00877	0.0149	CbGbCtD
Canagliflozin—ABCB1—Lisinopril—coronary artery disease	0.00877	0.0149	CbGbCtD
Canagliflozin—ABCB1—Timolol—coronary artery disease	0.00745	0.0127	CbGbCtD
Canagliflozin—CYP3A4—Gemfibrozil—coronary artery disease	0.00731	0.0124	CbGbCtD
Canagliflozin—ABCB1—Ezetimibe—coronary artery disease	0.00682	0.0116	CbGbCtD
Canagliflozin—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00664	0.0113	CbGbCtD
Canagliflozin—ABCB1—Captopril—coronary artery disease	0.00656	0.0111	CbGbCtD
Canagliflozin—CYP3A4—Clopidogrel—coronary artery disease	0.00634	0.0108	CbGbCtD
Canagliflozin—ABCB1—Simvastatin—coronary artery disease	0.00634	0.0108	CbGbCtD
Canagliflozin—ABCB1—Lovastatin—coronary artery disease	0.0062	0.0105	CbGbCtD
Canagliflozin—ABCB1—Pravastatin—coronary artery disease	0.0062	0.0105	CbGbCtD
Canagliflozin—CYP3A4—Eplerenone—coronary artery disease	0.00589	0.01	CbGbCtD
Canagliflozin—ABCB1—Atorvastatin—coronary artery disease	0.00565	0.00959	CbGbCtD
Canagliflozin—CYP3A4—Enalapril—coronary artery disease	0.00525	0.00892	CbGbCtD
Canagliflozin—ABCB1—Losartan—coronary artery disease	0.00517	0.00878	CbGbCtD
Canagliflozin—CYP3A4—Rosuvastatin—coronary artery disease	0.00408	0.00694	CbGbCtD
Canagliflozin—CYP3A4—Ezetimibe—coronary artery disease	0.00408	0.00694	CbGbCtD
Canagliflozin—CYP3A4—Simvastatin—coronary artery disease	0.0038	0.00645	CbGbCtD
Canagliflozin—CYP3A4—Pravastatin—coronary artery disease	0.00372	0.00631	CbGbCtD
Canagliflozin—CYP3A4—Lovastatin—coronary artery disease	0.00372	0.00631	CbGbCtD
Canagliflozin—CYP3A4—Atorvastatin—coronary artery disease	0.00338	0.00575	CbGbCtD
Canagliflozin—SLC5A1—cardiac ventricle—coronary artery disease	0.00327	0.0797	CbGeAlD
Canagliflozin—CYP3A4—Losartan—coronary artery disease	0.0031	0.00526	CbGbCtD
Canagliflozin—SLC5A1—myocardium—coronary artery disease	0.00307	0.075	CbGeAlD
Canagliflozin—UGT2B4—cardiac ventricle—coronary artery disease	0.00301	0.0734	CbGeAlD
Canagliflozin—UGT2B4—myocardium—coronary artery disease	0.00283	0.0691	CbGeAlD
Canagliflozin—SLC5A1—heart—coronary artery disease	0.00214	0.0523	CbGeAlD
Canagliflozin—SLC5A2—blood—coronary artery disease	0.00211	0.0515	CbGeAlD
Canagliflozin—SLC5A1—cardiovascular system—coronary artery disease	0.00202	0.0494	CbGeAlD
Canagliflozin—UGT2B4—heart—coronary artery disease	0.00198	0.0482	CbGeAlD
Canagliflozin—UGT2B4—cardiovascular system—coronary artery disease	0.00186	0.0455	CbGeAlD
Canagliflozin—SLC5A1—cardiac atrium—coronary artery disease	0.00183	0.0448	CbGeAlD
Canagliflozin—UGT2B4—cardiac atrium—coronary artery disease	0.00169	0.0412	CbGeAlD
Canagliflozin—ALB—heart—coronary artery disease	0.000623	0.0152	CbGeAlD
Canagliflozin—ORM1—blood—coronary artery disease	0.00053	0.0129	CbGeAlD
Canagliflozin—ABCC2—blood—coronary artery disease	0.000435	0.0106	CbGeAlD
Canagliflozin—CYP3A4—blood—coronary artery disease	0.000221	0.0054	CbGeAlD
Canagliflozin—ABCB1—heart—coronary artery disease	0.00021	0.00512	CbGeAlD
Canagliflozin—ABCB1—cardiovascular system—coronary artery disease	0.000198	0.00483	CbGeAlD
Canagliflozin—ABCB1—blood—coronary artery disease	0.000157	0.00382	CbGeAlD
Canagliflozin—Malnutrition—Timolol—coronary artery disease	0.000108	0.000665	CcSEcCtD
Canagliflozin—Erythema—Timolol—coronary artery disease	0.000108	0.000665	CcSEcCtD
Canagliflozin—Hypotension—Captopril—coronary artery disease	0.000108	0.000664	CcSEcCtD
Canagliflozin—Fatigue—Pravastatin—coronary artery disease	0.000107	0.000661	CcSEcCtD
Canagliflozin—Dry mouth—Losartan—coronary artery disease	0.000107	0.00066	CcSEcCtD
Canagliflozin—Shock—Furosemide—coronary artery disease	0.000107	0.00066	CcSEcCtD
Canagliflozin—Nervous system disorder—Furosemide—coronary artery disease	0.000107	0.000658	CcSEcCtD
Canagliflozin—Pruritus—Fenofibrate—coronary artery disease	0.000106	0.000656	CcSEcCtD
Canagliflozin—Constipation—Pravastatin—coronary artery disease	0.000106	0.000655	CcSEcCtD
Canagliflozin—Rash—Acetylsalicylic acid—coronary artery disease	0.000106	0.000655	CcSEcCtD
Canagliflozin—Hypersensitivity—Ezetimibe—coronary artery disease	0.000106	0.000655	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Valsartan—coronary artery disease	0.000106	0.000654	CcSEcCtD
Canagliflozin—Asthenia—Clopidogrel—coronary artery disease	0.000106	0.000654	CcSEcCtD
Canagliflozin—Dermatitis—Acetylsalicylic acid—coronary artery disease	0.000106	0.000654	CcSEcCtD
Canagliflozin—Skin disorder—Furosemide—coronary artery disease	0.000106	0.000652	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Olmesartan—coronary artery disease	0.000106	0.000651	CcSEcCtD
Canagliflozin—Asthenia—Lovastatin—coronary artery disease	0.000105	0.00065	CcSEcCtD
Canagliflozin—Pruritus—Clopidogrel—coronary artery disease	0.000105	0.000645	CcSEcCtD
Canagliflozin—Hypotension—Perindopril—coronary artery disease	0.000105	0.000645	CcSEcCtD
Canagliflozin—Infection—Losartan—coronary artery disease	0.000104	0.000643	CcSEcCtD
Canagliflozin—Angiopathy—Lisinopril—coronary artery disease	0.000104	0.000643	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Trandolapril—coronary artery disease	0.000104	0.000642	CcSEcCtD
Canagliflozin—Fatigue—Trandolapril—coronary artery disease	0.000104	0.000641	CcSEcCtD
Canagliflozin—Pruritus—Lovastatin—coronary artery disease	0.000104	0.000641	CcSEcCtD
Canagliflozin—Fatigue—Enalapril—coronary artery disease	0.000104	0.000639	CcSEcCtD
Canagliflozin—Asthenia—Ezetimibe—coronary artery disease	0.000103	0.000638	CcSEcCtD
Canagliflozin—Shock—Losartan—coronary artery disease	0.000103	0.000637	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Niacin—coronary artery disease	0.000103	0.000636	CcSEcCtD
Canagliflozin—Constipation—Trandolapril—coronary artery disease	0.000103	0.000636	CcSEcCtD
Canagliflozin—Urticaria—Valsartan—coronary artery disease	0.000103	0.000636	CcSEcCtD
Canagliflozin—Nausea—Rosuvastatin—coronary artery disease	0.000103	0.000635	CcSEcCtD
Canagliflozin—Nervous system disorder—Losartan—coronary artery disease	0.000103	0.000635	CcSEcCtD
Canagliflozin—Constipation—Enalapril—coronary artery disease	0.000103	0.000634	CcSEcCtD
Canagliflozin—Urticaria—Olmesartan—coronary artery disease	0.000103	0.000633	CcSEcCtD
Canagliflozin—Abdominal pain—Valsartan—coronary artery disease	0.000103	0.000633	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Telmisartan—coronary artery disease	0.000102	0.000631	CcSEcCtD
Canagliflozin—Fatigue—Telmisartan—coronary artery disease	0.000102	0.00063	CcSEcCtD
Canagliflozin—Abdominal pain—Olmesartan—coronary artery disease	0.000102	0.00063	CcSEcCtD
Canagliflozin—Pruritus—Ezetimibe—coronary artery disease	0.000102	0.000629	CcSEcCtD
Canagliflozin—Hypotension—Furosemide—coronary artery disease	0.000102	0.000627	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Pravastatin—coronary artery disease	0.000102	0.000626	CcSEcCtD
Canagliflozin—Constipation—Telmisartan—coronary artery disease	0.000101	0.000625	CcSEcCtD
Canagliflozin—Hypersensitivity—Simvastatin—coronary artery disease	0.000101	0.000624	CcSEcCtD
Canagliflozin—Asthenia—Eplerenone—coronary artery disease	0.000101	0.000624	CcSEcCtD
Canagliflozin—Angioedema—Ramipril—coronary artery disease	0.000101	0.000621	CcSEcCtD
Canagliflozin—Urticaria—Niacin—coronary artery disease	0.0001	0.000618	CcSEcCtD
Canagliflozin—Nausea—Acetylsalicylic acid—coronary artery disease	0.0001	0.000617	CcSEcCtD
Canagliflozin—Erythema—Lisinopril—coronary artery disease	0.0001	0.000617	CcSEcCtD
Canagliflozin—Malnutrition—Lisinopril—coronary artery disease	0.0001	0.000617	CcSEcCtD
Canagliflozin—Pruritus—Eplerenone—coronary artery disease	9.98e-05	0.000615	CcSEcCtD
Canagliflozin—Abdominal pain—Niacin—coronary artery disease	9.98e-05	0.000615	CcSEcCtD
Canagliflozin—Dizziness—Fenofibrate—coronary artery disease	9.95e-05	0.000614	CcSEcCtD
Canagliflozin—Fatigue—Captopril—coronary artery disease	9.94e-05	0.000613	CcSEcCtD
Canagliflozin—Syncope—Ramipril—coronary artery disease	9.89e-05	0.00061	CcSEcCtD
Canagliflozin—Urticaria—Pravastatin—coronary artery disease	9.87e-05	0.000609	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Trandolapril—coronary artery disease	9.87e-05	0.000608	CcSEcCtD
Canagliflozin—Asthenia—Simvastatin—coronary artery disease	9.86e-05	0.000608	CcSEcCtD
Canagliflozin—Constipation—Captopril—coronary artery disease	9.86e-05	0.000608	CcSEcCtD
Canagliflozin—Angioedema—Timolol—coronary artery disease	9.85e-05	0.000607	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Enalapril—coronary artery disease	9.83e-05	0.000606	CcSEcCtD
Canagliflozin—Abdominal pain—Pravastatin—coronary artery disease	9.82e-05	0.000606	CcSEcCtD
Canagliflozin—Hypotension—Losartan—coronary artery disease	9.81e-05	0.000605	CcSEcCtD
Canagliflozin—Dizziness—Clopidogrel—coronary artery disease	9.78e-05	0.000603	CcSEcCtD
Canagliflozin—Pruritus—Simvastatin—coronary artery disease	9.72e-05	0.0006	CcSEcCtD
Canagliflozin—Dizziness—Lovastatin—coronary artery disease	9.72e-05	0.000599	CcSEcCtD
Canagliflozin—Loss of consciousness—Ramipril—coronary artery disease	9.69e-05	0.000598	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Telmisartan—coronary artery disease	9.69e-05	0.000598	CcSEcCtD
Canagliflozin—Syncope—Timolol—coronary artery disease	9.67e-05	0.000596	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Perindopril—coronary artery disease	9.66e-05	0.000596	CcSEcCtD
Canagliflozin—Fatigue—Perindopril—coronary artery disease	9.65e-05	0.000595	CcSEcCtD
Canagliflozin—Urticaria—Trandolapril—coronary artery disease	9.59e-05	0.000591	CcSEcCtD
Canagliflozin—Constipation—Perindopril—coronary artery disease	9.57e-05	0.00059	CcSEcCtD
Canagliflozin—Hypersensitivity—Valsartan—coronary artery disease	9.56e-05	0.00059	CcSEcCtD
Canagliflozin—Convulsion—Ramipril—coronary artery disease	9.56e-05	0.000589	CcSEcCtD
Canagliflozin—Urticaria—Enalapril—coronary artery disease	9.55e-05	0.000589	CcSEcCtD
Canagliflozin—Abdominal pain—Trandolapril—coronary artery disease	9.54e-05	0.000588	CcSEcCtD
Canagliflozin—Dizziness—Ezetimibe—coronary artery disease	9.53e-05	0.000588	CcSEcCtD
Canagliflozin—Abdominal pain—Enalapril—coronary artery disease	9.5e-05	0.000586	CcSEcCtD
Canagliflozin—Rash—Fenofibrate—coronary artery disease	9.49e-05	0.000585	CcSEcCtD
Canagliflozin—Dermatitis—Fenofibrate—coronary artery disease	9.48e-05	0.000584	CcSEcCtD
Canagliflozin—Loss of consciousness—Timolol—coronary artery disease	9.48e-05	0.000584	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Captopril—coronary artery disease	9.43e-05	0.000581	CcSEcCtD
Canagliflozin—Urticaria—Telmisartan—coronary artery disease	9.42e-05	0.000581	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Furosemide—coronary artery disease	9.39e-05	0.000579	CcSEcCtD
Canagliflozin—Fatigue—Furosemide—coronary artery disease	9.38e-05	0.000578	CcSEcCtD
Canagliflozin—Abdominal pain—Telmisartan—coronary artery disease	9.37e-05	0.000578	CcSEcCtD
Canagliflozin—Dizziness—Eplerenone—coronary artery disease	9.33e-05	0.000575	CcSEcCtD
Canagliflozin—Rash—Clopidogrel—coronary artery disease	9.33e-05	0.000575	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	9.33e-05	0.000575	CcSEcCtD
Canagliflozin—Dermatitis—Clopidogrel—coronary artery disease	9.32e-05	0.000575	CcSEcCtD
Canagliflozin—Asthenia—Valsartan—coronary artery disease	9.31e-05	0.000574	CcSEcCtD
Canagliflozin—Constipation—Furosemide—coronary artery disease	9.3e-05	0.000574	CcSEcCtD
Canagliflozin—Hypersensitivity—Niacin—coronary artery disease	9.3e-05	0.000573	CcSEcCtD
Canagliflozin—Asthenia—Olmesartan—coronary artery disease	9.27e-05	0.000571	CcSEcCtD
Canagliflozin—Rash—Lovastatin—coronary artery disease	9.27e-05	0.000571	CcSEcCtD
Canagliflozin—Dermatitis—Lovastatin—coronary artery disease	9.26e-05	0.000571	CcSEcCtD
Canagliflozin—Pruritus—Valsartan—coronary artery disease	9.18e-05	0.000566	CcSEcCtD
Canagliflozin—Dry mouth—Ramipril—coronary artery disease	9.18e-05	0.000566	CcSEcCtD
Canagliflozin—Hypersensitivity—Pravastatin—coronary artery disease	9.16e-05	0.000564	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Perindopril—coronary artery disease	9.15e-05	0.000564	CcSEcCtD
Canagliflozin—Angioedema—Lisinopril—coronary artery disease	9.14e-05	0.000563	CcSEcCtD
Canagliflozin—Pruritus—Olmesartan—coronary artery disease	9.14e-05	0.000563	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	9.12e-05	0.000562	CcSEcCtD
Canagliflozin—Abdominal pain—Captopril—coronary artery disease	9.11e-05	0.000562	CcSEcCtD
Canagliflozin—Dizziness—Simvastatin—coronary artery disease	9.09e-05	0.00056	CcSEcCtD
Canagliflozin—Rash—Ezetimibe—coronary artery disease	9.09e-05	0.00056	CcSEcCtD
Canagliflozin—Dermatitis—Ezetimibe—coronary artery disease	9.08e-05	0.00056	CcSEcCtD
Canagliflozin—Asthenia—Niacin—coronary artery disease	9.06e-05	0.000558	CcSEcCtD
Canagliflozin—Fatigue—Losartan—coronary artery disease	9.05e-05	0.000558	CcSEcCtD
Canagliflozin—Dry mouth—Timolol—coronary artery disease	8.98e-05	0.000553	CcSEcCtD
Canagliflozin—Constipation—Losartan—coronary artery disease	8.98e-05	0.000553	CcSEcCtD
Canagliflozin—Syncope—Lisinopril—coronary artery disease	8.97e-05	0.000553	CcSEcCtD
Canagliflozin—Nausea—Fenofibrate—coronary artery disease	8.94e-05	0.000551	CcSEcCtD
Canagliflozin—Pruritus—Niacin—coronary artery disease	8.93e-05	0.00055	CcSEcCtD
Canagliflozin—Asthenia—Pravastatin—coronary artery disease	8.92e-05	0.00055	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Furosemide—coronary artery disease	8.9e-05	0.000549	CcSEcCtD
Canagliflozin—Rash—Eplerenone—coronary artery disease	8.89e-05	0.000548	CcSEcCtD
Canagliflozin—Urticaria—Perindopril—coronary artery disease	8.89e-05	0.000548	CcSEcCtD
Canagliflozin—Hypersensitivity—Trandolapril—coronary artery disease	8.89e-05	0.000548	CcSEcCtD
Canagliflozin—Dermatitis—Eplerenone—coronary artery disease	8.89e-05	0.000548	CcSEcCtD
Canagliflozin—Shock—Ramipril—coronary artery disease	8.86e-05	0.000546	CcSEcCtD
Canagliflozin—Hypersensitivity—Enalapril—coronary artery disease	8.86e-05	0.000546	CcSEcCtD
Canagliflozin—Abdominal pain—Perindopril—coronary artery disease	8.85e-05	0.000545	CcSEcCtD
Canagliflozin—Nervous system disorder—Ramipril—coronary artery disease	8.83e-05	0.000544	CcSEcCtD
Canagliflozin—Pruritus—Pravastatin—coronary artery disease	8.79e-05	0.000542	CcSEcCtD
Canagliflozin—Loss of consciousness—Lisinopril—coronary artery disease	8.79e-05	0.000542	CcSEcCtD
Canagliflozin—Nausea—Clopidogrel—coronary artery disease	8.79e-05	0.000542	CcSEcCtD
Canagliflozin—Skin disorder—Ramipril—coronary artery disease	8.74e-05	0.000539	CcSEcCtD
Canagliflozin—Infection—Timolol—coronary artery disease	8.74e-05	0.000539	CcSEcCtD
Canagliflozin—Hypersensitivity—Telmisartan—coronary artery disease	8.73e-05	0.000538	CcSEcCtD
Canagliflozin—Nausea—Lovastatin—coronary artery disease	8.73e-05	0.000538	CcSEcCtD
Canagliflozin—Rash—Simvastatin—coronary artery disease	8.67e-05	0.000534	CcSEcCtD
Canagliflozin—Dermatitis—Simvastatin—coronary artery disease	8.66e-05	0.000534	CcSEcCtD
Canagliflozin—Asthenia—Trandolapril—coronary artery disease	8.66e-05	0.000534	CcSEcCtD
Canagliflozin—Shock—Timolol—coronary artery disease	8.66e-05	0.000534	CcSEcCtD
Canagliflozin—Urticaria—Furosemide—coronary artery disease	8.64e-05	0.000533	CcSEcCtD
Canagliflozin—Nervous system disorder—Timolol—coronary artery disease	8.63e-05	0.000532	CcSEcCtD
Canagliflozin—Asthenia—Enalapril—coronary artery disease	8.62e-05	0.000532	CcSEcCtD
Canagliflozin—Abdominal pain—Furosemide—coronary artery disease	8.6e-05	0.00053	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Losartan—coronary artery disease	8.58e-05	0.000529	CcSEcCtD
Canagliflozin—Dizziness—Valsartan—coronary artery disease	8.58e-05	0.000529	CcSEcCtD
Canagliflozin—Nausea—Ezetimibe—coronary artery disease	8.56e-05	0.000528	CcSEcCtD
Canagliflozin—Skin disorder—Timolol—coronary artery disease	8.55e-05	0.000527	CcSEcCtD
Canagliflozin—Dizziness—Olmesartan—coronary artery disease	8.54e-05	0.000527	CcSEcCtD
Canagliflozin—Pruritus—Trandolapril—coronary artery disease	8.54e-05	0.000526	CcSEcCtD
Canagliflozin—Asthenia—Telmisartan—coronary artery disease	8.51e-05	0.000524	CcSEcCtD
Canagliflozin—Pruritus—Enalapril—coronary artery disease	8.5e-05	0.000524	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	8.46e-05	0.000521	CcSEcCtD
Canagliflozin—Hypotension—Ramipril—coronary artery disease	8.41e-05	0.000519	CcSEcCtD
Canagliflozin—Pruritus—Telmisartan—coronary artery disease	8.39e-05	0.000517	CcSEcCtD
Canagliflozin—Nausea—Eplerenone—coronary artery disease	8.38e-05	0.000517	CcSEcCtD
Canagliflozin—Dizziness—Niacin—coronary artery disease	8.35e-05	0.000515	CcSEcCtD
Canagliflozin—Urticaria—Losartan—coronary artery disease	8.34e-05	0.000514	CcSEcCtD
Canagliflozin—Dry mouth—Lisinopril—coronary artery disease	8.33e-05	0.000513	CcSEcCtD
Canagliflozin—Abdominal pain—Losartan—coronary artery disease	8.3e-05	0.000512	CcSEcCtD
Canagliflozin—Asthenia—Captopril—coronary artery disease	8.27e-05	0.00051	CcSEcCtD
Canagliflozin—Hypotension—Timolol—coronary artery disease	8.22e-05	0.000507	CcSEcCtD
Canagliflozin—Dizziness—Pravastatin—coronary artery disease	8.22e-05	0.000507	CcSEcCtD
Canagliflozin—Rash—Valsartan—coronary artery disease	8.18e-05	0.000505	CcSEcCtD
Canagliflozin—Dermatitis—Valsartan—coronary artery disease	8.18e-05	0.000504	CcSEcCtD
Canagliflozin—Nausea—Simvastatin—coronary artery disease	8.16e-05	0.000503	CcSEcCtD
Canagliflozin—Pruritus—Captopril—coronary artery disease	8.16e-05	0.000503	CcSEcCtD
Canagliflozin—Rash—Olmesartan—coronary artery disease	8.15e-05	0.000502	CcSEcCtD
Canagliflozin—Dermatitis—Olmesartan—coronary artery disease	8.14e-05	0.000502	CcSEcCtD
Canagliflozin—Infection—Lisinopril—coronary artery disease	8.11e-05	0.0005	CcSEcCtD
Canagliflozin—Shock—Lisinopril—coronary artery disease	8.03e-05	0.000495	CcSEcCtD
Canagliflozin—Asthenia—Perindopril—coronary artery disease	8.03e-05	0.000495	CcSEcCtD
Canagliflozin—Hypersensitivity—Furosemide—coronary artery disease	8.02e-05	0.000494	CcSEcCtD
Canagliflozin—Dizziness—Trandolapril—coronary artery disease	7.98e-05	0.000492	CcSEcCtD
Canagliflozin—Rash—Niacin—coronary artery disease	7.96e-05	0.000491	CcSEcCtD
Canagliflozin—Dermatitis—Niacin—coronary artery disease	7.95e-05	0.00049	CcSEcCtD
Canagliflozin—Dizziness—Enalapril—coronary artery disease	7.95e-05	0.00049	CcSEcCtD
Canagliflozin—Skin disorder—Lisinopril—coronary artery disease	7.93e-05	0.000489	CcSEcCtD
Canagliflozin—Pruritus—Perindopril—coronary artery disease	7.92e-05	0.000488	CcSEcCtD
Canagliflozin—Dizziness—Telmisartan—coronary artery disease	7.84e-05	0.000483	CcSEcCtD
Canagliflozin—Rash—Pravastatin—coronary artery disease	7.84e-05	0.000483	CcSEcCtD
Canagliflozin—Dermatitis—Pravastatin—coronary artery disease	7.83e-05	0.000483	CcSEcCtD
Canagliflozin—Asthenia—Furosemide—coronary artery disease	7.81e-05	0.000481	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ramipril—coronary artery disease	7.77e-05	0.000479	CcSEcCtD
Canagliflozin—Fatigue—Ramipril—coronary artery disease	7.76e-05	0.000478	CcSEcCtD
Canagliflozin—Hypersensitivity—Losartan—coronary artery disease	7.73e-05	0.000477	CcSEcCtD
Canagliflozin—Nausea—Valsartan—coronary artery disease	7.71e-05	0.000475	CcSEcCtD
Canagliflozin—Pruritus—Furosemide—coronary artery disease	7.7e-05	0.000475	CcSEcCtD
Canagliflozin—Constipation—Ramipril—coronary artery disease	7.7e-05	0.000475	CcSEcCtD
Canagliflozin—Nausea—Olmesartan—coronary artery disease	7.67e-05	0.000473	CcSEcCtD
Canagliflozin—Hypotension—Lisinopril—coronary artery disease	7.63e-05	0.00047	CcSEcCtD
Canagliflozin—Dizziness—Captopril—coronary artery disease	7.62e-05	0.00047	CcSEcCtD
Canagliflozin—Rash—Trandolapril—coronary artery disease	7.61e-05	0.000469	CcSEcCtD
Canagliflozin—Dermatitis—Trandolapril—coronary artery disease	7.6e-05	0.000469	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Timolol—coronary artery disease	7.6e-05	0.000468	CcSEcCtD
Canagliflozin—Fatigue—Timolol—coronary artery disease	7.59e-05	0.000468	CcSEcCtD
Canagliflozin—Rash—Enalapril—coronary artery disease	7.58e-05	0.000467	CcSEcCtD
Canagliflozin—Dermatitis—Enalapril—coronary artery disease	7.57e-05	0.000467	CcSEcCtD
Canagliflozin—Asthenia—Losartan—coronary artery disease	7.53e-05	0.000464	CcSEcCtD
Canagliflozin—Nausea—Niacin—coronary artery disease	7.5e-05	0.000462	CcSEcCtD
Canagliflozin—Rash—Telmisartan—coronary artery disease	7.47e-05	0.000461	CcSEcCtD
Canagliflozin—Dermatitis—Telmisartan—coronary artery disease	7.47e-05	0.00046	CcSEcCtD
Canagliflozin—Pruritus—Losartan—coronary artery disease	7.43e-05	0.000458	CcSEcCtD
Canagliflozin—Dizziness—Perindopril—coronary artery disease	7.4e-05	0.000456	CcSEcCtD
Canagliflozin—Nausea—Pravastatin—coronary artery disease	7.38e-05	0.000455	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ramipril—coronary artery disease	7.36e-05	0.000454	CcSEcCtD
Canagliflozin—Rash—Captopril—coronary artery disease	7.27e-05	0.000448	CcSEcCtD
Canagliflozin—Dermatitis—Captopril—coronary artery disease	7.26e-05	0.000448	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Timolol—coronary artery disease	7.2e-05	0.000444	CcSEcCtD
Canagliflozin—Dizziness—Furosemide—coronary artery disease	7.2e-05	0.000444	CcSEcCtD
Canagliflozin—Nausea—Trandolapril—coronary artery disease	7.17e-05	0.000442	CcSEcCtD
Canagliflozin—Urticaria—Ramipril—coronary artery disease	7.15e-05	0.000441	CcSEcCtD
Canagliflozin—Nausea—Enalapril—coronary artery disease	7.14e-05	0.00044	CcSEcCtD
Canagliflozin—Abdominal pain—Ramipril—coronary artery disease	7.12e-05	0.000439	CcSEcCtD
Canagliflozin—Rash—Perindopril—coronary artery disease	7.06e-05	0.000435	CcSEcCtD
Canagliflozin—Dermatitis—Perindopril—coronary artery disease	7.05e-05	0.000435	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Lisinopril—coronary artery disease	7.05e-05	0.000435	CcSEcCtD
Canagliflozin—Nausea—Telmisartan—coronary artery disease	7.04e-05	0.000434	CcSEcCtD
Canagliflozin—Fatigue—Lisinopril—coronary artery disease	7.04e-05	0.000434	CcSEcCtD
Canagliflozin—Urticaria—Timolol—coronary artery disease	6.99e-05	0.000431	CcSEcCtD
Canagliflozin—Constipation—Lisinopril—coronary artery disease	6.98e-05	0.00043	CcSEcCtD
Canagliflozin—Abdominal pain—Timolol—coronary artery disease	6.96e-05	0.000429	CcSEcCtD
Canagliflozin—Dizziness—Losartan—coronary artery disease	6.94e-05	0.000428	CcSEcCtD
Canagliflozin—Rash—Furosemide—coronary artery disease	6.86e-05	0.000423	CcSEcCtD
Canagliflozin—Dermatitis—Furosemide—coronary artery disease	6.85e-05	0.000423	CcSEcCtD
Canagliflozin—Nausea—Captopril—coronary artery disease	6.85e-05	0.000422	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Lisinopril—coronary artery disease	6.68e-05	0.000412	CcSEcCtD
Canagliflozin—Nausea—Perindopril—coronary artery disease	6.65e-05	0.00041	CcSEcCtD
Canagliflozin—Hypersensitivity—Ramipril—coronary artery disease	6.63e-05	0.000409	CcSEcCtD
Canagliflozin—Rash—Losartan—coronary artery disease	6.62e-05	0.000408	CcSEcCtD
Canagliflozin—Dermatitis—Losartan—coronary artery disease	6.61e-05	0.000408	CcSEcCtD
Canagliflozin—Urticaria—Lisinopril—coronary artery disease	6.49e-05	0.0004	CcSEcCtD
Canagliflozin—Hypersensitivity—Timolol—coronary artery disease	6.48e-05	0.0004	CcSEcCtD
Canagliflozin—Nausea—Furosemide—coronary artery disease	6.46e-05	0.000398	CcSEcCtD
Canagliflozin—Asthenia—Ramipril—coronary artery disease	6.46e-05	0.000398	CcSEcCtD
Canagliflozin—Abdominal pain—Lisinopril—coronary artery disease	6.45e-05	0.000398	CcSEcCtD
Canagliflozin—Pruritus—Ramipril—coronary artery disease	6.37e-05	0.000393	CcSEcCtD
Canagliflozin—Asthenia—Timolol—coronary artery disease	6.31e-05	0.000389	CcSEcCtD
Canagliflozin—Nausea—Losartan—coronary artery disease	6.24e-05	0.000384	CcSEcCtD
Canagliflozin—Pruritus—Timolol—coronary artery disease	6.23e-05	0.000384	CcSEcCtD
Canagliflozin—Hypersensitivity—Lisinopril—coronary artery disease	6.01e-05	0.000371	CcSEcCtD
Canagliflozin—Dizziness—Ramipril—coronary artery disease	5.95e-05	0.000367	CcSEcCtD
Canagliflozin—Asthenia—Lisinopril—coronary artery disease	5.86e-05	0.000361	CcSEcCtD
Canagliflozin—Dizziness—Timolol—coronary artery disease	5.82e-05	0.000359	CcSEcCtD
Canagliflozin—Pruritus—Lisinopril—coronary artery disease	5.78e-05	0.000356	CcSEcCtD
Canagliflozin—Rash—Ramipril—coronary artery disease	5.68e-05	0.00035	CcSEcCtD
Canagliflozin—Dermatitis—Ramipril—coronary artery disease	5.67e-05	0.00035	CcSEcCtD
Canagliflozin—Rash—Timolol—coronary artery disease	5.55e-05	0.000342	CcSEcCtD
Canagliflozin—Dermatitis—Timolol—coronary artery disease	5.54e-05	0.000342	CcSEcCtD
Canagliflozin—Dizziness—Lisinopril—coronary artery disease	5.4e-05	0.000333	CcSEcCtD
Canagliflozin—Nausea—Ramipril—coronary artery disease	5.35e-05	0.00033	CcSEcCtD
Canagliflozin—Nausea—Timolol—coronary artery disease	5.23e-05	0.000322	CcSEcCtD
Canagliflozin—Rash—Lisinopril—coronary artery disease	5.15e-05	0.000317	CcSEcCtD
Canagliflozin—Dermatitis—Lisinopril—coronary artery disease	5.14e-05	0.000317	CcSEcCtD
Canagliflozin—Nausea—Lisinopril—coronary artery disease	4.85e-05	0.000299	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—APOB—coronary artery disease	5.95e-06	5.39e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ARNTL—coronary artery disease	5.94e-06	5.38e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HADH—coronary artery disease	5.94e-06	5.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLCB3—coronary artery disease	5.94e-06	5.38e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—coronary artery disease	5.91e-06	5.35e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA5—coronary artery disease	5.88e-06	5.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOB—coronary artery disease	5.82e-06	5.28e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—coronary artery disease	5.81e-06	5.27e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—F2—coronary artery disease	5.79e-06	5.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FN1—coronary artery disease	5.79e-06	5.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK1—coronary artery disease	5.79e-06	5.25e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—coronary artery disease	5.78e-06	5.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—P4HB—coronary artery disease	5.76e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCH1—coronary artery disease	5.76e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AK1—coronary artery disease	5.76e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—coronary artery disease	5.73e-06	5.2e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—coronary artery disease	5.73e-06	5.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—coronary artery disease	5.73e-06	5.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	5.71e-06	5.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—coronary artery disease	5.7e-06	5.17e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—LPL—coronary artery disease	5.68e-06	5.14e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G1B—coronary artery disease	5.66e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA2—coronary artery disease	5.63e-06	5.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX2—coronary artery disease	5.63e-06	5.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G2A—coronary artery disease	5.63e-06	5.1e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	5.59e-06	5.07e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SULT1A1—coronary artery disease	5.56e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG5—coronary artery disease	5.56e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HK1—coronary artery disease	5.56e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX4—coronary artery disease	5.56e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—coronary artery disease	5.54e-06	5.02e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	5.53e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLCD1—coronary artery disease	5.52e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MDH2—coronary artery disease	5.52e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPAT—coronary artery disease	5.52e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UGCG—coronary artery disease	5.52e-06	5.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HADHA—coronary artery disease	5.5e-06	4.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA1—coronary artery disease	5.43e-06	4.92e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—coronary artery disease	5.43e-06	4.92e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—coronary artery disease	5.42e-06	4.91e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD36—coronary artery disease	5.39e-06	4.89e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LPA—coronary artery disease	5.37e-06	4.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—VCAN—coronary artery disease	5.33e-06	4.83e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPP2CA—coronary artery disease	5.33e-06	4.83e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PGM1—coronary artery disease	5.32e-06	4.82e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDOA—coronary artery disease	5.29e-06	4.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—APOA1—coronary artery disease	5.26e-06	4.76e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLCB3—coronary artery disease	5.2e-06	4.71e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA5—coronary artery disease	5.15e-06	4.67e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—DCN—coronary artery disease	5.14e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CKB—coronary artery disease	5.14e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PYGB—coronary artery disease	5.14e-06	4.65e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—coronary artery disease	5.11e-06	4.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—coronary artery disease	5.08e-06	4.6e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—P4HB—coronary artery disease	5.05e-06	4.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—coronary artery disease	5.03e-06	4.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDH2—coronary artery disease	5e-06	4.53e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G1B—coronary artery disease	4.96e-06	4.49e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—coronary artery disease	4.95e-06	4.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	4.87e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LIPC—coronary artery disease	4.87e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HBA1—coronary artery disease	4.87e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2C19—coronary artery disease	4.87e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3C2A—coronary artery disease	4.87e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AGT—coronary artery disease	4.86e-06	4.4e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOC3—coronary artery disease	4.84e-06	4.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLIN1—coronary artery disease	4.83e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—COX5B—coronary artery disease	4.83e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PFKFB3—coronary artery disease	4.83e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DLAT—coronary artery disease	4.83e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM2—coronary artery disease	4.83e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE1—coronary artery disease	4.82e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LDLR—coronary artery disease	4.81e-06	4.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	4.81e-06	4.35e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOE—coronary artery disease	4.76e-06	4.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC9A1—coronary artery disease	4.75e-06	4.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—coronary artery disease	4.75e-06	4.31e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APOA1—coronary artery disease	4.7e-06	4.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCLC—coronary artery disease	4.7e-06	4.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CETP—coronary artery disease	4.7e-06	4.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—VCAN—coronary artery disease	4.67e-06	4.23e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SDC1—coronary artery disease	4.65e-06	4.21e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDOA—coronary artery disease	4.64e-06	4.2e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—APOA1—coronary artery disease	4.61e-06	4.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—coronary artery disease	4.6e-06	4.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SULT1E1—coronary artery disease	4.58e-06	4.15e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	4.5e-06	4.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—DCN—coronary artery disease	4.5e-06	4.08e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—JAK2—coronary artery disease	4.47e-06	4.05e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—coronary artery disease	4.43e-06	4.01e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMA6—coronary artery disease	4.39e-06	3.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMB5—coronary artery disease	4.39e-06	3.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDH2—coronary artery disease	4.38e-06	3.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKR1B1—coronary artery disease	4.37e-06	3.96e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HK2—coronary artery disease	4.37e-06	3.96e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CTGF—coronary artery disease	4.29e-06	3.88e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HBA1—coronary artery disease	4.27e-06	3.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LIPC—coronary artery disease	4.27e-06	3.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2C19—coronary artery disease	4.27e-06	3.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3C2A—coronary artery disease	4.27e-06	3.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMGCR—coronary artery disease	4.25e-06	3.85e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GOT2—coronary artery disease	4.25e-06	3.85e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOC3—coronary artery disease	4.24e-06	3.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LDLR—coronary artery disease	4.22e-06	3.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC27A1—coronary artery disease	4.19e-06	3.79e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC9A1—coronary artery disease	4.17e-06	3.77e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—coronary artery disease	4.17e-06	3.77e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—coronary artery disease	4.14e-06	3.76e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCLC—coronary artery disease	4.12e-06	3.73e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CETP—coronary artery disease	4.12e-06	3.73e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CPT1B—coronary artery disease	4.11e-06	3.72e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LCAT—coronary artery disease	4.11e-06	3.72e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—coronary artery disease	4.11e-06	3.72e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—POMC—coronary artery disease	4.09e-06	3.7e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SDC1—coronary artery disease	4.07e-06	3.69e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—coronary artery disease	4.04e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA4—coronary artery disease	4.03e-06	3.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLCB1—coronary artery disease	3.91e-06	3.54e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PDHA1—coronary artery disease	3.89e-06	3.53e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCLM—coronary artery disease	3.89e-06	3.53e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMA6—coronary artery disease	3.85e-06	3.48e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMB5—coronary artery disease	3.85e-06	3.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	3.83e-06	3.47e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCA1—coronary artery disease	3.79e-06	3.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TXNRD1—coronary artery disease	3.77e-06	3.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP11B2—coronary artery disease	3.77e-06	3.42e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CTGF—coronary artery disease	3.76e-06	3.4e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—coronary artery disease	3.73e-06	3.38e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMGCR—coronary artery disease	3.72e-06	3.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GOT2—coronary artery disease	3.72e-06	3.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC22A3—coronary artery disease	3.71e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GGT1—coronary artery disease	3.67e-06	3.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GOT1—coronary artery disease	3.67e-06	3.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ARNTL—coronary artery disease	3.66e-06	3.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HADH—coronary artery disease	3.66e-06	3.32e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—coronary artery disease	3.65e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—coronary artery disease	3.56e-06	3.23e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA2—coronary artery disease	3.47e-06	3.14e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX2—coronary artery disease	3.47e-06	3.14e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G2A—coronary artery disease	3.47e-06	3.14e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SULT1A1—coronary artery disease	3.43e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG5—coronary artery disease	3.43e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HK1—coronary artery disease	3.43e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX4—coronary artery disease	3.43e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLCB1—coronary artery disease	3.42e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HADHA—coronary artery disease	3.39e-06	3.07e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA1—coronary artery disease	3.35e-06	3.03e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCA1—coronary artery disease	3.32e-06	3.01e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—coronary artery disease	3.32e-06	3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LPA—coronary artery disease	3.31e-06	3e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—coronary artery disease	3.3e-06	2.99e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARGC1A—coronary artery disease	3.26e-06	2.96e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—coronary artery disease	3.26e-06	2.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—coronary artery disease	3.25e-06	2.94e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GOT1—coronary artery disease	3.21e-06	2.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GGT1—coronary artery disease	3.21e-06	2.91e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAT—coronary artery disease	3.21e-06	2.9e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLCB3—coronary artery disease	3.21e-06	2.9e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA5—coronary artery disease	3.17e-06	2.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOB—coronary artery disease	3.11e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—P4HB—coronary artery disease	3.11e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	3.05e-06	2.77e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—coronary artery disease	3.04e-06	2.76e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—coronary artery disease	3.03e-06	2.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK1—coronary artery disease	2.99e-06	2.7e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LPL—coronary artery disease	2.97e-06	2.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—coronary artery disease	2.9e-06	2.63e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—coronary artery disease	2.89e-06	2.62e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—VCAN—coronary artery disease	2.88e-06	2.61e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARGC1A—coronary artery disease	2.86e-06	2.59e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDOA—coronary artery disease	2.86e-06	2.59e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—coronary artery disease	2.85e-06	2.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD36—coronary artery disease	2.82e-06	2.56e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAT—coronary artery disease	2.81e-06	2.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPP2CA—coronary artery disease	2.79e-06	2.53e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DCN—coronary artery disease	2.77e-06	2.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOB—coronary artery disease	2.73e-06	2.47e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH2—coronary artery disease	2.7e-06	2.44e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—coronary artery disease	2.68e-06	2.42e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—coronary artery disease	2.65e-06	2.4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LIPC—coronary artery disease	2.63e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HBA1—coronary artery disease	2.63e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2C19—coronary artery disease	2.63e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	2.63e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOC3—coronary artery disease	2.61e-06	2.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LPL—coronary artery disease	2.6e-06	2.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LDLR—coronary artery disease	2.6e-06	2.35e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—coronary artery disease	2.59e-06	2.35e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC9A1—coronary artery disease	2.57e-06	2.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—coronary artery disease	2.57e-06	2.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AGT—coronary artery disease	2.54e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—coronary artery disease	2.54e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CETP—coronary artery disease	2.54e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCLC—coronary artery disease	2.54e-06	2.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SDC1—coronary artery disease	2.51e-06	2.27e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOE—coronary artery disease	2.49e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD36—coronary artery disease	2.47e-06	2.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APOA1—coronary artery disease	2.46e-06	2.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPP2CA—coronary artery disease	2.44e-06	2.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMA6—coronary artery disease	2.37e-06	2.15e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMB5—coronary artery disease	2.37e-06	2.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.36e-06	2.14e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—coronary artery disease	2.34e-06	2.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CTGF—coronary artery disease	2.31e-06	2.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMGCR—coronary artery disease	2.29e-06	2.08e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GOT2—coronary artery disease	2.29e-06	2.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AGT—coronary artery disease	2.23e-06	2.02e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOE—coronary artery disease	2.18e-06	1.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—coronary artery disease	2.17e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APOA1—coronary artery disease	2.16e-06	1.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—POMC—coronary artery disease	2.14e-06	1.94e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—coronary artery disease	2.12e-06	1.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLCB1—coronary artery disease	2.11e-06	1.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCA1—coronary artery disease	2.04e-06	1.85e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—coronary artery disease	2.01e-06	1.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GOT1—coronary artery disease	1.98e-06	1.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GGT1—coronary artery disease	1.98e-06	1.79e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—coronary artery disease	1.9e-06	1.72e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—POMC—coronary artery disease	1.88e-06	1.7e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—coronary artery disease	1.87e-06	1.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—coronary artery disease	1.78e-06	1.61e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	1.76e-06	1.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—coronary artery disease	1.75e-06	1.59e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAT—coronary artery disease	1.73e-06	1.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—coronary artery disease	1.71e-06	1.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—coronary artery disease	1.71e-06	1.55e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOB—coronary artery disease	1.68e-06	1.52e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—coronary artery disease	1.64e-06	1.48e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—coronary artery disease	1.64e-06	1.48e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—coronary artery disease	1.63e-06	1.48e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LPL—coronary artery disease	1.6e-06	1.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—coronary artery disease	1.57e-06	1.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD36—coronary artery disease	1.52e-06	1.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP2CA—coronary artery disease	1.51e-06	1.36e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—coronary artery disease	1.5e-06	1.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—coronary artery disease	1.44e-06	1.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AGT—coronary artery disease	1.37e-06	1.24e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOE—coronary artery disease	1.34e-06	1.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APOA1—coronary artery disease	1.33e-06	1.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—coronary artery disease	1.17e-06	1.06e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—POMC—coronary artery disease	1.16e-06	1.05e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—coronary artery disease	1.05e-06	9.54e-06	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—coronary artery disease	1.05e-06	9.52e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—coronary artery disease	1.01e-06	9.13e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—coronary artery disease	9.21e-07	8.35e-06	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—coronary artery disease	9.2e-07	8.34e-06	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—coronary artery disease	8.58e-07	7.77e-06	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—coronary artery disease	7.52e-07	6.81e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—coronary artery disease	5.67e-07	5.14e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—coronary artery disease	4.63e-07	4.2e-06	CbGpPWpGaD
